Loading...
XHKG
8049
Market cap140mUSD
May 02, Last price  
1.94HKD
1D
2.11%
1Q
33.79%
Jan 2017
19.75%
Name

Jilin Province Huinan Changlong Bio-pharmacy Co Ltd

Chart & Performance

D1W1MN
P/E
5.49
P/S
1.15
EPS
0.33
Div Yield, %
3.54%
Shrs. gr., 5y
—
Rev. gr., 5y
6.41%
Revenues
881m
+4.71%
81,889,00069,522,00097,284,000127,124,000152,766,000200,630,000274,294,000353,247,000457,746,000601,715,000539,134,000654,119,000645,303,000647,672,000645,885,000622,250,000705,456,000841,586,000841,545,000881,157,000
Net income
184m
+24.32%
8,017,0003,037,00012,378,00014,989,00022,076,00035,891,00050,893,00058,754,00079,274,000132,785,000117,638,000142,670,000144,402,000161,216,000144,726,000126,558,000143,283,000193,565,000148,207,000184,250,000
CFO
220m
-30.48%
17,841,00029,357,00017,096,00040,643,00014,397,00055,169,00022,909,00050,893,00082,694,00049,434,000151,613,000123,823,000146,507,000138,813,000132,509,000151,227,000215,090,000203,992,000315,947,000219,652,000
Dividend
Jun 18, 20240.06862 HKD/sh
Earnings
May 28, 2025

Profile

Jilin Province Huinan Changlong Bio-pharmacy Company Limited engages in the manufacture and distribution of Chinese medicines and pharmaceutical products in the People's Republic of China. It offers tablets, capsules, pills, Chinese medicine pretreatment and extraction products, powders for injections, lyophilized powder for injections, small volume injection solutions, APIs, and granules. The company markets its products under the Changlong and Qing Tong brands. The company was formerly known as Jilin Province Huinan Biochemical Pharmaceutical Company Limited. Jilin Province Huinan Changlong Bio-pharmacy Company Limited was founded in 1989 and is based in Kowloon, Hong Kong.
URL
http://www.jlchanglong.com
IPO date
May 24, 2001
Employees
928
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
881,157
4.71%
841,545
0.00%
841,586
19.30%
Cost of revenue
718,093
719,910
722,561
Unusual Expense (Income)
NOPBT
163,064
121,635
119,025
NOPBT Margin
18.51%
14.45%
14.14%
Operating Taxes
22,910
50,107
3,780
Tax Rate
14.05%
41.19%
3.18%
NOPAT
140,154
71,528
115,245
Net income
184,250
24.32%
148,207
-23.43%
193,565
35.09%
Dividends
(34,947)
(283,670)
(28,218)
Dividend yield
4.52%
30.87%
5.79%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
72,400
8,400
400
Long-term debt
72,000
Deferred revenue
34,954
40,966
Other long-term liabilities
3,934
41,155
1,961
Net debt
(1,212,183)
(1,299,348)
(324,606)
Cash flow
Cash from operating activities
219,652
315,947
203,992
CAPEX
(11,021)
(31,841)
(11,317)
Cash from investing activities
(310,934)
109,043
(117,971)
Cash from financing activities
(25,009)
(186,454)
(27,714)
FCF
218,589
304,627
130,425
Balance
Cash
539,030
655,591
1,032,126
Long term investments
745,553
724,157
(707,120)
Excess cash
1,240,525
1,337,671
282,927
Stockholders' equity
1,545,274
1,396,040
1,527,958
Invested Capital
500,377
264,264
1,314,473
ROIC
36.66%
9.06%
11.83%
ROCE
9.36%
7.59%
7.44%
EV
Common stock shares outstanding
560,250
560,250
560,250
Price
1.38
-15.85%
1.64
88.51%
0.87
-26.27%
Market cap
773,145
-15.85%
918,810
88.51%
487,418
-26.27%
EV
(439,038)
(380,538)
162,812
EBITDA
190,205
149,195
152,629
EV/EBITDA
1.07
Interest
2,027
515
477
Interest/NOPBT
1.24%
0.42%
0.40%